Massachusetts-based gene-editing biotech company Intellia Therapeutics and Texas-based genetic medicines company ReCode Therapeutics have entered an agreement to develop gene-editing treatments for cystic fibrosis (CF).
As part of the agreement, Intellia will receive pre-specified development and commercial milestone payments as well as royalties from sales. Intellia will also have an option to lead the commercialization in the US for specific programs.
The partnership will integrate Intellia’s CRISPR-based gene editing platform and ReCode’s lipid nanoparticle delivery system to accurately modify CF-causing gene mutations. Intellia will oversee the design of the editing strategy while ReCode will handle clinical development and commercialization.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.